ReviewCurrent gastroenterology reports2025
Is Eosinophilic Colitis a Forerunner of Inflammatory Bowel Disease?
Review in Current gastroenterology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rediscovering eosinophil identity through tissue adaptation.Nature immunology · 2026Review
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewEosinophilic colitis (EoC) has an increasing association with inflammatory bowel disease (IBD), and there is a paucity of data on the natural history of EoC. Here, we provide a comprehensive overview of EoC and critically evaluate the evidence supporting its potential association with, or evolution into IBD. RECENT
findingsExperts currently classify EoC as one of the eosinophilic gastrointestinal disorders (EGID) beyond eosinophilic esophagitis (EoE). Transcriptomic analyses have demonstrated a distinct molecular signature for EoC. However, recent studies suggest that a subset of patients with EoC may progress to develop IBD. The key predictive factors include high eosinophilic density on colonic biopsy and poor response or relapse following standard therapy. Emerging evidence suggests that EoC may precede or overlap with IBD. The lack of standardized diagnostic criteria and limited longitudinal data hinder firm conclusions and warrant future prospective multicenter studies. Available current literature suggests that clinicians should be vigilant with persistent or severe symptomatic patients despite standard treatment to evaluate for IBD.
Indexed as
Identifiers
40785002What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.